PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
PET scans may let melanoma patients stop therapy early
Disease control OngoingThis study tests whether doctors can safely stop standard anti-PD-1 immunotherapy earlier than usual for people with advanced melanoma that cannot be removed surgically. Using PET/CT scans and tumor biopsies as guides, researchers aim to see if shorter treatment still keeps the c…
Matched conditions: PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 26, 2026 06:26 UTC
-
New drug combo shows promise in fight against advanced melanoma
Disease control OngoingThis early-phase study tests whether adding an experimental drug (VX15/2503) to standard immunotherapy (ipilimumab or nivolumab) helps the immune system attack stage III melanoma before surgery. About 41 adults with resectable melanoma will receive different combinations of these…
Matched conditions: PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 06:23 UTC
-
New hope for kidney transplant patients facing advanced skin cancer
Disease control OngoingThis early-stage study tests a combination of drugs (tacrolimus, nivolumab, and ipilimumab) in 12 kidney transplant recipients who have advanced skin cancers that cannot be surgically removed. The goal is to see if this treatment can shrink or control the cancer while keeping the…
Matched conditions: PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New combo aims to tame Immunotherapy's side effects in advanced cancers
Disease control OngoingThis study tests whether adding tocilizumab to standard immunotherapy (ipilimumab and nivolumab) can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive the combination to see if it is safer and still eff…
Matched conditions: PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New combo aims to shrink melanoma before surgery
Disease control OngoingThis study tests whether adding an experimental drug (CMP-001) to the immunotherapy pembrolizumab works better than pembrolizumab alone for people with melanoma that can be surgically removed. About 60 adults with stage III melanoma will receive treatment before surgery to see if…
Matched conditions: PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
Immune cell attack: new combo shows promise against tough melanoma
Disease control OngoingThis early-phase study tests whether giving a patient's own lab-grown immune cells (TILs) along with the immunotherapy drug pembrolizumab is safe and feasible for people with advanced melanoma that has spread to lymph nodes. The treatment aims to shrink tumors before surgery. Onl…
Matched conditions: PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: Richard Wu • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
Melanoma Survivors' immunotherapy side effects under the microscope
Knowledge-focused OngoingThis study looks at side effects and symptom burden in people with melanoma who are receiving immunotherapy after surgery. Researchers will track side effects, quality of life, depression, and fatigue over 24 months. They also want to see if certain blood markers are linked to th…
Matched conditions: PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 26, 2026 06:24 UTC
-
Facebook group aims to boost skin checks in young melanoma families
Knowledge-focused OngoingThis study looks at whether a private Facebook group can help young adults (ages 18-39) diagnosed with early-stage melanoma and their close family members do more thorough skin checks and protect themselves from the sun. About 1,160 participants from New Jersey, California, and T…
Matched conditions: PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated May 22, 2026 13:53 UTC